Remove tag hepatitis-c
article thumbnail

Grand Rounds October 20, 2023: A National Initiative to Eliminate Hepatitis C in the United States – Why This Matters to Clinical Trialists (Rachael L. Fleurence, PhD, MSc; Joshua M. Sharfstein, MD)

Rethinking Clinical Trials

with the rate of reported acute Hepatitis C cases increasing 400% during 2010-2020. Untreated, chronic Hepatitis C infection leads to liver damage, liver cancer, and death. There is now a cure for Hepatitis C, but many people are not able to access it. Rates are the highest among 20-39-year-olds.

article thumbnail

Oslo Medicines Initiative asks how to balance innovation incentivisation with security of access

pharmaphorum

“It has become clear that the medicines of the 20 th century, the so-called blockbuster era, are gradually being replaced by drugs designed for smaller groups, specific indication, and even for individual patients,” said Jo De C**k, CEO of Belgium’s National Institute for Health and Disability Insurance. Finding solutions.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet

The Pharma Data

The S-Trimer vaccine candidates and adjuvants are expected to be stable long term at refrigerator temperatures (2-8 o C) and have demonstrated stability at room temperature for at least two months, making these constructs suitable for broad global distribution based on current results. About Trimer-Tag© Technology.

article thumbnail

Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates

The Pharma Data

Preliminary results from stability studies have demonstrated that S-Trimer is stable at 2-8 o C for at least six months (longer-term stability studies are ongoing) and stable at room temperature and 40 o C for at least one month, in line with the adjuvants tested. About Trimer-Tag © Technology. About COVID-19 S-Trimer Vaccine.

article thumbnail

Targeting a human protein may stop Ebola virus in its tracks

The Pharma Data

In fact, antiviral therapies designed to treat viruses such as hepatitis C (Sofosbuvir/SOVALDI) work by blocking viral polymerase. This special enzyme, once fused to Ebola virus polymerase, enables the polymerase to add a molecular tag to any other protein it interacts with. The problems with Ebola polymerase.

Protein 52
article thumbnail

With an $11 billion price tag, the White House pitches a plan to end hepatitis C

STAT News

WASHINGTON — The Biden administration is calling on Congress to fund a more than $11 billion program to eliminate hepatitis C in the United States. The annual request for the Substance Abuse and Mental Health Services Administration also comes in below the hepatitis C topline, at $10.8 Read the rest…

Drugs 116